BridgeBio Oncology Therapeutics, Inc

BBOT Healthcare Biotechnology

In the quarter to June 2026, EPS fell 25.3% and free cash flow fell 88.8%, each against the same quarter a year earlier.

2.82 0.13 −4.41%
Market cap
$236.5M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Dec '23 Dec '24 Dec '25
Current Ratio
— 8.10 12.34
Net Debt/EBITDA
— 1.93 2.93
Debt/Equity
— 0.00 0.00
ROE
— 0.00% (115.33%)
ROA
— (90.41%) (43.76%)
ROIC
— 0.00% 0.00%
Return on Tangible Assets
— (53.20%) (33.65%)
Average Days of Receivables
— 0.00 0.00
Free Cash Flow per Share
— (4,269.46) (3.68)
Book value per Share
— (13,847.83) 13.20
Free Cash Flow
— (55.08) (114.50)
Other line items

Show all line items

Columns are period end dates